caa a22 4500 60623649X CHVBK 20210128101248.0 cr unu---uuuuu 210128e20150201xx s 000 0 eng 10.1007/s11010-014-2271-4 doi (NATIONALLICENCE)springer-10.1007/s11010-014-2271-4 PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice [Elektronische Daten] [Kunal Kapoor, Esha Singla, Bijayani Sahu, Amarjit Naura] We have previously shown that PARP-1 inhibition provides protection against lung inflammation in the context of asthma and acute lung injury. Olaparib is a potent new generation PARP inhibitor that has been approved for human testing. The present work was designed to evaluate its beneficial potential against LPS-induced acute lung injury and acute kidney injury upon intratracheal administration of the endotoxin in mice. Administration of olaparib at different doses, 30min after LPS treatment showed that single intraperitoneal injection of the drug at 5mg/kgb.wt. reduced the total number of inflammatory cells particularly neutrophils in the lungs. This was associated with reduced pulmonary edema as the total protein content in the bronchoalveolar fluid was found to be decreased substantially. Olaparib provided strong protection against LPS-mediated secondary kidney injury as reflected by restoration of serum levels of urea, creatinine, and uric acid toward normal. The drug restored the LPS-mediated redox imbalance toward normal in lung and kidney tissues as assessed by measuring malondialdehyde and GSH levels. Finally, RT-PCR data revealed that olaparib downregulates the LPS-induced expression of NF-κB-dependent genes namely TNF-α, IL-1β, and VCAM-1 in the lungs without altering the expression of total p65NF-κB. Overall, the data suggest that olaparib has a strong potential to protect against LPS-induced lung injury and associated dysfunctioning of kidney in mice. Given the fact that olaparib is approved by FDA for human testing, our findings can pave the way for testing of the drug on humans inflicted with acute lung injury. Springer Science+Business Media New York, 2014 PARP nationallicence Olaparib nationallicence LPS nationallicence Acute lung injury nationallicence Acute kidney injury nationallicence Kapoor Kunal Department of Biochemistry, Panjab University, 160014, Chandigarh, India aut Singla Esha Department of Biochemistry, Panjab University, 160014, Chandigarh, India aut Sahu Bijayani Department of Biochemistry, Panjab University, 160014, Chandigarh, India aut Naura Amarjit Department of Biochemistry, Panjab University, 160014, Chandigarh, India aut Molecular and Cellular Biochemistry Springer US; http://www.springer-ny.com 400/1-2(2015-02-01), 153-162 0300-8177 400:1-2<153 2015 400 11010 https://doi.org/10.1007/s11010-014-2271-4 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s11010-014-2271-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kapoor Kunal Department of Biochemistry, Panjab University, 160014, Chandigarh, India aut NATIONALLICENCE 700 1- Singla Esha Department of Biochemistry, Panjab University, 160014, Chandigarh, India aut NATIONALLICENCE 700 1- Sahu Bijayani Department of Biochemistry, Panjab University, 160014, Chandigarh, India aut NATIONALLICENCE 700 1- Naura Amarjit Department of Biochemistry, Panjab University, 160014, Chandigarh, India aut NATIONALLICENCE 773 0- Molecular and Cellular Biochemistry Springer US; http://www.springer-ny.com 400/1-2(2015-02-01), 153-162 0300-8177 400:1-2<153 2015 400 11010